BioStem Technologies, Inc. (BSEM) Form S-1 — Jul 29, 2026
BioStem Technologies has filed an S-1 to register 3.57 million shares of common stock for resale by a selling stockholder, representing roughly 20% of the current outstanding shares. The shares are being registered following a May 2026 private placement where the investor purchased shares at $3.35 each, including anti-dilution protection down to a floor price of $0.70. The company will not receive any proceeds from these sales, which could put downward pressure on the stock price. The company disclosed substantial doubt about its ability to continue as a going concern due to a history of net losses and recent regulatory changes to Medicare reimbursement.
Key figures
- Net Income
- -6.6 million
- Total Debt
- 0
- Floor Price
- 0.70
- Cash Position
- 0
- Gross Proceeds
- 2.5 million
- Purchase Price
- 3.35
- Shares Offered
- 3,571,429
- Shares Outstanding
- 17,831,861
- Accumulated Deficit
- 21.2 million
- Net Loss Pro Forma2025
- (9,349,385)
- Revenue Pro Forma2025
- 76,554,847
- Cms Reimbursement Rate
- 127.14
- Cms Revenue Drop Percent
- 95%
- Net Loss Pro Forma Q12026
- (8,040,071)
- Revenue Pro Forma Q12026
- 7,621,856
- Catalyze Acquisition Consideration
- 10.0 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.